In the third, final, and by most reckonings most inconsequential, national debate of the US presidential election, vice ...

Starting January 1, 2025, most Blue Shield commercial members using Fresenius Kabi's adalimumab-aacf (a Humira biosimilar) ...

The lawsuit, originally filed by the Roofers Local No. 149 Pension Fund in 2023, alleges that Amgen misled shareholders by ...

Seven new clinical trial grants were awarded under the Orphan Product Grants Program during the fiscal year (FY) 2024, ...

Incyte's first attempt to get FDA approval for its PD-1 inhibitor Zynyz for squamous cell carcinoma of the anal canal (SCAC) was knocked back by the FDA, but new data could get the programme back ...

The original mpox outbreak began in 2022, but case numbers have rumbled on, despite countermeasures. Ben Hargreaves finds that a new variant of the virus is spreading more rapidly, and the ...

In a bid to put litigation over the safety of its talc products into the rearview mirror, Johnson & Johnson has added another $1.1 billion to its settlement offer, according to media reports.

Vaxcyte's new pneumococcal vaccine may only have phase 1/2 results behind it, but analysts are already predicting it could be a major competitor to rival shots from Pfizer and MSD. Just-reported ...

The 4th Mitochondrial Dysfunction Drug Development Summit returns in 2024, to unite pharma, biotech and academia on cutting-edge research and pipeline updates expanding the therapeutic ...

A diagnosis identifies a patient’s health problem and is a key to accessing the care and treatment they need. A diagnostic error is the failure to establish a ...

The month-long standoff between the US Health Resources and Services Administration (HRSA) and Johnson & Johnson came to an ...

UCB taps new UK head. Belgium-based global biopharmaceutical company UCB welcomed Nico Reynders as its new general manager ...